April 28, 2025
UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025…
Pharmaceuticals, Biotechnology and Life Sciences
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025…
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) — On April 25, 2025, the 66th (Spring 2025) National Pharmaceutical Machinery Exposition &…
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder…
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of…
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced…
GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed…
Plenary presentation of data showing primary efficacy endpoint met – significant analgesia across all dosesSignificant improvement in all signs and…
Dividend confirmationRegulated information – 25 april 2025 The general shareholders meeting of 25 April 2025 has approved the annual accounts…
LOS ANGELES, April 26, 2025 (GLOBE NEWSWIRE) — Gluco6 is a natural blood sugar support supplement emerging as a popular…